
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


ESSA Pharma Inc (EPIX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: EPIX (1-star) is a SELL. SELL since 5 days. Profits (-54.91%). Updated daily EoD!
1 Year Target Price $1.74
1 Year Target Price $1.74
0 | Strong Buy |
0 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.87% | Avg. Invested days 41 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.35M USD | Price to earnings Ratio - | 1Y Target Price 1.74 |
Price to earnings Ratio - | 1Y Target Price 1.74 | ||
Volume (30-day avg) 2 | Beta 1.56 | 52 Weeks Range 0.22 - 7.88 | Updated Date 08/30/2025 |
52 Weeks Range 0.22 - 7.88 | Updated Date 08/30/2025 | ||
Dividends yield (FY) 87.56% | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate -0.17 | Actual -0.0902 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.25% | Return on Equity (TTM) -21.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -98265734 | Price to Sales(TTM) - |
Enterprise Value -98265734 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.09 | Shares Outstanding 47308400 | Shares Floating 33355729 |
Shares Outstanding 47308400 | Shares Floating 33355729 | ||
Percent Insiders 5.64 | Percent Institutions 74.16 |
Upturn AI SWOT
ESSA Pharma Inc

Company Overview
History and Background
ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer. Founded in 2009, it has progressed through preclinical and clinical stages with its lead drug candidate, accelerating the development of oncology treatments.
Core Business Areas
- Androgen Receptor Signaling: ESSA Pharma Inc. is focused on disrupting androgen receptor signaling, a key driver of prostate cancer. This includes small molecule inhibitors targeting the N-terminal domain (NTD) of the androgen receptor.
Leadership and Structure
ESSA Pharma Inc's leadership team includes a CEO, Chief Medical Officer, and other key executives overseeing research, development, and operations. The company has a board of directors providing strategic guidance.
Top Products and Market Share
Key Offerings
- EPI-738: EPI-738 is ESSA Pharma's lead investigational product for prostate cancer. It is designed to block the N-terminal domain of the androgen receptor. Market share data is not yet applicable as the product is in clinical development. Competitors include developers of other androgen receptor inhibitors, like ARASENS, Janssen, and Orion. Clinical stage revenue.
Market Dynamics
Industry Overview
The prostate cancer treatment market is a substantial and growing sector of the pharmaceutical industry. The prevalence of prostate cancer and the increasing aging population are major drivers. Significant unmet needs exist for patients with advanced or resistant disease.
Positioning
ESSA Pharma is positioned as a developer of next-generation androgen receptor inhibitors. Its competitive advantage lies in its unique approach of targeting the N-terminal domain (NTD) of the AR, which differs from existing treatments.
Total Addressable Market (TAM)
The prostate cancer therapeutics market is projected to reach over $12 billion in the coming years. ESSA Pharma aims to capture a portion of this market by providing new treatment options for patients resistant to existing therapies.
Upturn SWOT Analysis
Strengths
- Novel drug target (N-terminal domain of AR)
- Strong intellectual property portfolio
- Experienced management team
- Potential for improved efficacy and safety profile
Weaknesses
- Single product pipeline
- Reliance on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High regulatory risk
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
- Increasing prevalence of prostate cancer
Threats
- Failure to achieve positive clinical trial results
- Competition from established prostate cancer therapies
- Changes in regulatory landscape
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
Competitive Landscape
ESSA Pharma's competitive advantage lies in its novel drug target, however it faces strong competition from established companies with significantly larger resources and existing market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily reflected in the advancement of its lead drug candidate through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and potential commercialization or partnerships.
Recent Initiatives: Recent initiatives include advancing the Phase 1/2 clinical trial of EPI-738, securing additional funding, and expanding its intellectual property portfolio.
Summary
ESSA Pharma is a clinical-stage company with a promising novel drug target for prostate cancer. Its future hinges on the success of its clinical trials and its ability to secure partnerships or funding. The company faces significant risks due to its single product pipeline and reliance on clinical trial outcomes, but it is working to secure itself in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ESSA Pharma Inc. website
- SEC filings
- Industry reports
- Clinical trial data
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ESSA Pharma Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2015-07-09 | President, CEO & Director Dr. David Ross Parkinson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.essapharma.com |
Full time employees 35 | Website https://www.essapharma.com |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.